Azacitidine Injection
Phase 1/2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tuberculosis, Pulmonary
Conditions
Tuberculosis, Pulmonary
Trial Timeline
Oct 1, 2022 → May 1, 2023
NCT ID
NCT03941496About Azacitidine Injection
Azacitidine Injection is a phase 1/2 stage product being developed by Bristol Myers Squibb for Tuberculosis, Pulmonary. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03941496. Target conditions include Tuberculosis, Pulmonary.
What happened to similar drugs?
3 of 5 similar drugs in Tuberculosis, Pulmonary were approved
Approved (3) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03941496 | Phase 1/2 | Withdrawn |
Competing Products
20 competing products in Tuberculosis, Pulmonary